PLIANT THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| AdditionalPaid-InCapital · AccumulatedOtherComprehensive(Loss) Gain · AccumulatedDeficit · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2023 | 59,921,002 | $6 | $972,973 | $345 | $(499,748) | $473,576 |
| Issuance of common stock under benefit plans | 939,836 | — | 3,207 | — | — | 3,207 |
| Stock-based compensation expense | — | — | 37,626 | — | — | 37,626 |
| Net unrealized loss on short-term investments | — | — | — | (24) | — | (24) |
| Net loss | — | — | — | — | (210,304) | (210,304) |
| Balance at December 31, 2024 | 60,860,838 | $6 | $1,013,806 | $321 | $(710,052) | $304,081 |
| Issuance of common stock under benefit plans | 588,452 | — | 570 | — | — | 570 |
| Stock-based compensation expense | — | — | 26,234 | — | — | 26,234 |
| Net unrealized loss on short-term investments | — | — | — | (336) | — | (336) |
| Net loss | — | — | — | — | (149,344) | (149,344) |
| Balance at December 31, 2025 | 61,449,290 | $6 | $1,040,610 | $(15) | $(859,396) | $181,205 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.